Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 9/20 | 0.68 |
| ▸ | CHRM5 | P08912 | 6/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 2/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6339711 | 1.00 | MME (0.68) | MMECHRM5CHRM1CHRM4CHRM3 | |
| SCHEMBL8270265 | 0.99 | MME (0.67) | MMECHRM5CHRM1CHRM4CHRM3 | |
| SCHEMBL8270495 | 0.89 | MME (0.54) | MMECHRM5CHRM1CHRM4CHRM3 | |
| SCHEMBL8271281 | 0.84 | MME (0.65) | MMEMMP1 | |
| SCHEMBL6349761 | 0.81 | MME (1.00) | MMERAB9ANPC1MMP1 | |
| SCHEMBL489205 | 0.81 | MME (1.00) | MMEMMP1 | |
| SCHEMBL6340259 | 0.81 | MME (0.82) | MMEPOLBMMP1 | |
| SCHEMBL1620495 | 0.81 | MME (1.00) | MMEMMP1 | |
| SCHEMBL8268609 | 0.77 | RAB9A (0.45) | MMECHRM5CHRM1CHRM4CHRM3 | |
| SCHEMBL8269280 | 0.75 | MME (0.53) | MMERAB9AMMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106611-A1 | N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER INC | 2004-06-03 | — | — | US | claimed |
| EP-1373192-A1 | N-PHENPROPYLCYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS NEP INHIBITORS FOR FSAD | Pfizer Limited (GB) | 2004-01-02 | — | — | EP | claimed |
| US-6660756-B2 | N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER INC. | 2003-12-09 | — | — | US | claimed |
| US-20030105132-A1 | N-phenpropylcuclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER INC. | 2003-06-05 | — | — | US | claimed |
| WO-2002079143-A1 | N-PHENPROPYLCYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS NEP INHIBITORS FOR FSAD | PFIZER LIMITED (GB) | 2002-10-10 | — | — | WO | claimed |
| US-6849649-B2 | N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER INC. (US) | 2005-02-01 | — | — | US | disclosed |
| US-20040106611-A1 | N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER INC | 2004-06-03 | — | — | US | disclosed |
| EP-1373192-A1 | N-PHENPROPYLCYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS NEP INHIBITORS FOR FSAD | Pfizer Limited (GB) | 2004-01-02 | — | — | EP | disclosed |
| US-6660756-B2 | N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER INC. | 2003-12-09 | — | — | US | disclosed |
| US-20030105132-A1 | N-phenpropylcuclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER INC. | 2003-06-05 | — | — | US | disclosed |
| WO-2002079143-A1 | N-PHENPROPYLCYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS NEP INHIBITORS FOR FSAD | PFIZER LIMITED (GB) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105132-A1 | N-phenpropylcuclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PREP, ENGASE, ENPEP | MME 14/4885CHRM5 669/4885CHRM1 1265/4885 |
| US-20040106611-A1 | N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PREP, ENGASE, ENPEP | MME 15/4885CHRM5 760/4885CHRM1 1446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.